Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCENT 2 maintenance study of mirikizumab in moderately to severely active ulcerative colitis
MOH_2019-01-07_004892Phase 3Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mirikizumab in autoimmune colitis (3 arms), sponsored by Eli Lilly and Company. Planned start Sep 2018; status: not yet recruiting.
02
Drugs
mirikizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2019-01-07_004892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-01-07_004892.